Regeneron

News

Spokesman from MD Anderson Cancer Center

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.

News

Regeneron drug on track to be second FOP treatment

There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

News

Regeneron preps filings for myasthenia gravis drug

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Regeneron's Libtayo stakes out new territory in skin cancer

Why Regeneron is giving away sequencing “for free”, with Ali...

Regeneron drug on track to be second FOP treatment

Regeneron preps filings for myasthenia gravis drug

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Regeneron

Editor's Picks